Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets
To de-risk and shorten path to critical structural and biophysical insights that inform structure-based drug design
Cambridge, UK, Boston MA, USA and Villigen, Switzerland, 17 February 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership. The collaboration brings together eProtein Discovery’s™ rapid multiplex membrane protein…
Nuclera and leadxpro Partner to Accelerate Structure-based Drug Design for Complex Membrane Proteins
Cancer Research Horizons, the innovation engine of Cancer Research UK, is proud to announce the addition of the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study dataset to its growing portfolio of commercially licensable data assets.
Developed by a team led by Professor Rebecca Fitzgerald at the University of Cambridge, the OCCAMS dataset represents one of the world’s largest and most comprehensive collections of clinically linked, multi-omics data from oesophageal adenocarcinoma patients. This unique resource includes clinical data from over 4,000 patients across 27…
- HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease
- Clinical Advisory Board formed to support progression of HRN001 into first-in-human studies in 2027
- Dr Andy Billinton, CSO will present preclinical data at the upcoming CHDI Foundation Huntington’s Disease Therapeutics Conference
Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today…
Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppression
The study which compared MB310, a precision microbiome medicine, with placebo in 29 ulcerative colitis (UC) patients met its primary and secondary objectives to demonstrate safety, efficacy and engraftment:
Efficacy:
Clinical remission achieved in 63.2% (12/19) MB310 treated patients vs 30.0% (3/10) in placebo treated patients (ITT analysis)
All MB310 treated patients who entered follow-up (n=12) achieved sustained clinical remission and complete resolution of…
LONDON, UK – February 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Concept Life Sciences and is pleased to announce the placement of Dr. Adam Davenport as Chief Scientific Officer (CSO).Concept Life Sciences is a leading global contract research organization (CRO) specializing in integrated drug discovery, development, and analytical services. The company provides consultative and collaborative solutions that enable biotech and pharmaceutical partners…
Amsbio has introduced an expanded range of Skeletal Muscle Differentiation Kits designed to reproducibly convert pluripotent or embryonic stem cells into myoblasts with high regenerative potential.
Using a simple 3-step process of media changes and cell passaging – these advanced kits can typically achieve 70% MF20-positive myotubes. The highly efficient protocol employed by the kit does not require genetic intervention or cell sorting, thereby saving you valuable time.
Not only do Amsbio Skeletal Muscle Differentiation kits work with all pluripotent stem…
We are pleased to announce the shortlist for the One Nucleus Awards 2026.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders.
Best Therapeutic R&D Programme of the Year:⭐Resolution Therapeutics⭐Serenatis Bio⭐Trimtech Therapeutics Ltd
Best Use of Emerging Technology of the Year:⭐Ignota Labs⭐Constructive Bio⭐Nuclera Ltd
Best Industry and Not for Profit Collaboration of the Year:⭐ LifeArc⭐ Cellestial Health Ltd⭐Aspire Biosciences
Most Innovative Professional Services Company of the…
Sandwich, UK - 9 February 2026: To mark National Apprenticeship Week (9 - 15 February), Kent’s science and technology hub Discovery Park is calling for more young people to consider higher apprenticeships as a route into rewarding careers in STEM (Science, Technology, Engineering, and Maths).
Last year, 3,850 young people in Kent started a higher apprenticeship programme, a 22% increase on the previous year. Higher apprenticeships include degree apprenticeships - where students gain a full undergraduate or master’s degree without student fees - and also Higher National Diplomas and…
Royston, 3 February 2026.Pharmagene Discovery Services Ltd. (‘Pharmagene’) is pleased to announce its launch and that its co-founding management team has completed the asset purchase of an established human tissue laboratory business based near Cambridge, UK. The business is specialised in the performance of laboratory-based research services using consented human tissue across both preclinical and clinical settings. Originally founded back in 1996 and returning to its original trading name, the business has a unique heritage of conducting hundreds of human tissue studies for clients around…
Starting something new is hard – particularly within the fast-moving life science sector. Step forward Accelerate@Babraham, the Babraham Research Campus’ bio-incubator, founded out of a desire to support and nurture early-stage ventures; bringing to bear an unrivalled network of experts, mentors and investors and data-driven, comprehensive business analysis and support to equip these young enterprises with the skills, confidence and network connections to enable success.
Now in our eighth year, Accelerate@Babraham companies have raised £72.5m and have a current portfolio value estimated at…